About Visterra (NASDAQ:VIST)
Visterra Inc is a United States-based biotechnology company. The Company uses its Atomic Interaction Network analysis to identify disease targets and design effective therapeutics. The Company's technology is based on its Hierotope Platform, which identifies an area, or epitope, on the target protein, glycoprotein or glycan that is fundamental to its structure and function. The Company's Hierotope Platform is able to identify the region of the protein, or epitope, which is structurally constrained, and thus prevented from mutation over time or under immunological or therapeutic pressure. Its technology for creating potent and therapeutics is powered by the Company's computational tools and techniques, the core of which is called Atomic Interaction Network (AIN) analysis.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Visterra (NASDAQ:VIST) Frequently Asked Questions
What is Visterra's stock symbol?
Visterra trades on the NASDAQ under the ticker symbol "VIST."
Who are some of Visterra's key competitors?
Some companies that are related to Visterra include Medivation (MDVN), Bioverativ (BIVV), Kite Pharma (KITE), Juno Therapeutics (JUNO), Shire-Nps Pharmaceuticals (NPSP), Auspex Pharmaceuticals (ASPX), Insmed (INSM), Ignyta (RXDX), Madrigal Pharmaceuticals (MDGL), Clinigen Group (CLIN), Neuroderm (NDRM), Sucampo Pharmaceuticals (SCMP), Raptor Pharmaceutical (RPTP), Cascadian Therapeutics (CASC), Oxford BioMedica (OXB), BioTime (BTX), Biotie Therapies (BITI) and Circassia Pharmaceuticals (CIR).
When did Visterra IPO?
(VIST) raised $51 million in an initial public offering (IPO) on the week of January 30th 2017. The company issued 3,900,000 shares at $12.00-$14.00 per share. Leerink Partners and Stifel served as the underwriters for the IPO and Needham & Company, Wedbus and PacGrow were co-managers.
Has Visterra been receiving favorable news coverage?
News headlines about VIST stock have trended somewhat positive on Monday, Accern reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Visterra earned a daily sentiment score of 0.19 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 45.61 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Visterra?
Shares of VIST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Visterra?
Visterra's mailing address is 1 Kendall Sq Ste B3301, CAMBRIDGE, MA 02139-1604, United States. The biotechnology company can be reached via phone at +1-617-4981070.
MarketBeat Community Rating for Visterra (VIST)MarketBeat's community ratings are surveys of what our community members think about Visterra and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Visterra (NASDAQ:VIST) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Earnings History for Visterra (NASDAQ:VIST)
No earnings announcements for this company have been tracked by MarketBeat.com
Visterra (NASDAQ:VIST) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Visterra (NASDAQ:VIST)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Visterra (NASDAQ VIST)
No insider trades for this company have been tracked by MarketBeat.com
Visterra (NASDAQ VIST) News Headlines
No headlines for this company have been tracked by MarketBeat.com
Visterra (NASDAQ:VIST) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Visterra (NASDAQ:VIST) Income Statement, Balance Sheet and Cash Flow Statement
Visterra (NASDAQ VIST) Stock Chart for Monday, March, 19, 2018